Search Results

Introgen Therapeutics: long road ahead for its early compounds.

Subjects: ADENOVIRUSES; CLINICAL trials; CANCER treatmentINTROGEN Therapeutics Inc. INTROGEN Therapeutics Inc. INTROGEN Therapeutics Inc. 878974153 ; VIRRX Inc.

• Source: PharmaWatch: Cancer. July 2004, Vol. 3 Issue 7, p15-16. 2p.

Record details

Boehringer Ingelheim GmbH SWOT Analysis.

Subjects: BIOPHARMACEUTICS; PHARMACEUTICAL industry; SWOT analysisINGELHEIM am Rhein (Germany)BOEHRINGER Ingelheim GmbH

• Source: Boehringer Ingelheim GmbH SWOT Analysis; 4/26/2017, p1-9, 9p

Record details

Bristol-Myers Squibb Company SWOT Analysis.

Subjects: PHARMACEUTICAL industry; SWOT analysisNEW York (N.Y.)BRISTOL-Myers Squibb Co.

• Source: Bristol-Myers Squibb Company SWOT Analysis; 11/24/2016, p1-9, 9p

Record details

Introgen Therapeutics: long road ahead for its early compounds.

Subjects: CLINICAL trials; CANCER treatment; VIRUSESINTROGEN Therapeutics Inc. INTROGEN Therapeutics Inc. INTROGEN Therapeutics Inc. 878974153

• Source: PharmaWatch: Monthly Review. July 2004, Vol. 3 Issue 7, p41-41. 1p.

Record details

United Kingdom.

• Source: Country Commerce. United Kingdom; Oct2015, p1-96, 98p

Record details

Biotechnology Industry Profile: France.

Subjects: *BIOTECHNOLOGY industries; *BIOTECHNOLOGY; *TECHNOLOGYFRANCE

• Source: Biotechnology Industry Profile: France. Aug2011, p1. 32p.

Record details